Pulmocide Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Oct 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Process for preparing a compound useful to treat mycoses (US 11,661,415) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 9, 2027The maintenance fee for Compound useful to treat mycoses (US 10,344,022) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for Compound useful to treat mycoses (US 10,450,304) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 2 fees due May 12 to 26, 2027 · next May 12
- 1 fee due Jun 24, 2027The maintenance fee for Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof (US 10,513,511) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Compounds (US 10,626,126) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,732,098 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 9,926,335 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 10,035,810 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 10,189,863 | 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 10,273,249 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 10,472,375 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 10,106,531 | Compound useful to treat mycoses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,344,022 | Compound useful to treat mycoses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,450,304 | Compound useful to treat mycoses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,487,073 | Compounds which are used in the preparation of the compound of formula (I) In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded